Axsome Therapeutics (NASDAQ:AXSM) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $190.00 price objective on the stock. HC Wainwright also issued estimates for Axsome Therapeutics’ Q3 2025 earnings at $0.47 EPS and Q4 2025 earnings at $1.33 EPS.

Other research analysts also recently issued reports about the stock. Truist Financial reissued a buy rating and issued a $150.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, March 26th. UBS Group began coverage on Axsome Therapeutics in a report on Tuesday, February 6th. They issued a buy rating and a $111.00 target price for the company. Mizuho lifted their price target on Axsome Therapeutics from $108.00 to $109.00 and gave the company a buy rating in a report on Thursday, March 28th. Royal Bank of Canada increased their price objective on Axsome Therapeutics from $123.00 to $128.00 and gave the stock an outperform rating in a research note on Tuesday, March 26th. Finally, Cantor Fitzgerald reaffirmed an overweight rating and set a $107.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $121.92.

Axsome Therapeutics Trading Down 2.6 %

Axsome Therapeutics stock opened at $73.68 on Tuesday. Axsome Therapeutics has a 1 year low of $55.02 and a 1 year high of $98.40. The firm’s 50 day moving average price is $73.84 and its two-hundred day moving average price is $75.72. The firm has a market cap of $3.50 billion, a price-to-earnings ratio of -11.55 and a beta of 1.13. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.52 and a current ratio of 3.63.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Tuesday, February 20th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.48. The business had revenue of $71.53 million during the quarter, compared to analyst estimates of $70.38 million. Axsome Therapeutics had a negative return on equity of 70.67% and a negative net margin of 88.41%. On average, research analysts predict that Axsome Therapeutics will post -3.75 EPS for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 24,662 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Axsome Therapeutics news, COO Mark L. Jacobson sold 24,662 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Roger Jeffs sold 29,976 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the transaction, the director now owns 120,756 shares of the company’s stock, valued at $8,416,693.20. The disclosure for this sale can be found here. Corporate insiders own 24.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXSM. Commonwealth Equity Services LLC grew its position in Axsome Therapeutics by 30.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 6,741 shares of the company’s stock worth $471,000 after acquiring an additional 1,558 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Axsome Therapeutics by 1.1% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 18,734 shares of the company’s stock worth $1,309,000 after acquiring an additional 197 shares during the period. Bank of New York Mellon Corp lifted its position in Axsome Therapeutics by 4.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 168,006 shares of the company’s stock valued at $11,742,000 after acquiring an additional 6,920 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Axsome Therapeutics by 12.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,724 shares of the company’s stock valued at $540,000 after acquiring an additional 872 shares in the last quarter. Finally, Strs Ohio grew its stake in shares of Axsome Therapeutics by 28.4% during the 3rd quarter. Strs Ohio now owns 9,500 shares of the company’s stock worth $663,000 after acquiring an additional 2,100 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.